This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Photo: American Heart Association tim.hodson Tue, 01/14/2025 - 16:05 Jan. 9, 2025 Gender-based racism through microaggressions may be linked to higher bloodpressure postpartum and beyond, according to new research published in Hypertension , a peer-reviewed journal of the American Heart Association.
tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., tim.hodson Tue, 03/11/2025 - 11:19 Mar. 10, 2025-- Corcept Therapeutics Inc., will establish the prevalence of endogenous hypercortisolism in patients with resistant hypertension.
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.
tim.hodson Fri, 02/14/2025 - 14:32 Feb. tim.hodson Fri, 02/14/2025 - 14:32 Feb. The presentation,"Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction,"was deliveredby Marat Fudim, M.D., Advanced Heart Failure Cardiologist, Duke Health on Feb.
tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. The Company anticipates initiating the trial in the first quarter of 2025.
It becomes effective January 1, 2025, and is expected to remain effective for up to three years. This is a major step forward in the reimbursement available for the Paradise uRDN system, creating additional financial support for hospitals and physicians to provide this novel and effective therapy to their uncontrolled hypertension patients.”
Hypertension, Volume 82, Issue 1 , Page 149-159, January 1, 2025. BACKGROUND:Patient education is needed to perform home bloodpressure measurement (HBPM) according to bloodpressure (BP) guidelines. Guideline recommendations for HBPM were not always followed by survey participants.
Stroke, Volume 56, Issue 1 , Page 105-112, January 1, 2025. BACKGROUND:The focus for reducing hypertension-related cardiovascular disease is the management of bloodpressure. Participants were stratified by duration of recognized hypertension: normotensive (0 years), 5 years, 6 to 20 years, or 21+ years.
Hypertension, Volume 82, Issue 1 , Page 26-35, January 1, 2025. Hypertension management involves using bloodpressure and other biometric data from connected devices and generative AI to communicate with patients and health care professionals.
Stroke, Volume 56, Issue Suppl_1 , Page ATP21-ATP21, February 1, 2025. IntroductionThe efficacy of bloodpressure (BP) reduction of Sacubitril/valsartan has been proved in hypertension patients, yet not in patients with acute ischemic stroke (AIS).
tim.hodson Mon, 03/10/2025 - 11:17 At the Cardiovascular Research Technologies (CRT) 2025 conference in Washington, D.C., The analysis of data from SCAARon the Prevail coronary paclitaxel drug-coated balloon (DCB) will be presented as a late-breaking clinical trial at Cardiovascular Research Technologies (CRT) 2025 in Washington, D.C.
Stroke, Volume 56, Issue Suppl_1 , Page ANS7-ANS7, February 1, 2025. Controlling hypertension after a hemorrhage is the primary intervention to limit the risk of hematoma expansion (HE) and the sequelae of secondary injury.
Nature Reviews Cardiology, Published online: 07 February 2025; doi:10.1038/s41569-025-01131-4 Hypertension is the leading cause of death globally but has low rates of diagnosis and treatment.
Hypertension, Volume 82, Issue 1 , Page 106-117, January 1, 2025. BACKGROUND:Neurogenic orthostatic hypotension (nOH) causes pathological falls in standing bloodpressure that may or may not be symptomatic. Whether nOH symptoms reflect greater CBFv falls is also unclear.
Stroke, Volume 56, Issue Suppl_1 , Page ATP27-ATP27, February 1, 2025. Introduction:Hypertension (HTN) is a leading cause of vascular cognitive impairment and bloodpressure (BP) control is linked with improved brain health.
Stroke, Volume 56, Issue Suppl_1 , Page ANS9-ANS9, February 1, 2025. Background:High BloodPressure (HBP) issue is high among African American aging populations living in rural areas.
Stroke, Volume 56, Issue Suppl_1 , Page ANS1-ANS1, February 1, 2025. Data showed SAH patients who presented to the Emergency Department (ED) with headache (HA) and hypertension frequently had long wait times before evaluation by a provider. A total of nine direct arriving patients were reviewed over a one-year period.
Stroke, Volume 56, Issue Suppl_1 , Page A21-A21, February 1, 2025. Introduction:For stroke survivors, bloodpressure (BP) reduction significantly lowers the risk of recurrence; a 10mmHg decrease in systolic BP is associated with a 20% risk reduction.
High bloodpressure is one of the biggest killers on the planet. Most people do not know when they have high bloodpressure. Managing bloodpressure is about getting good data. Most people, if they are lucky, have their bloodpressure measured in their doctors’ office once a year.
Stroke, Volume 56, Issue Suppl_1 , Page AWP141-AWP141, February 1, 2025. In unadjusted analysis, factors significantly associated with troponin testing were a triage complaint of chest pain, older age, higher mean systolic BP, hypertension, diabetes, obesity, stroke or TIA, congestive heart failure, or coronary disease.
Stroke, Volume 56, Issue Suppl_1 , Page ATP30-ATP30, February 1, 2025. We have shown that the brain CD38 expression and enzymatic activity are increased in the setting of hypertension (HTN) including spontaneously hypertensive stroke prone rat and angiotensin-II (Ang-II) induced HTN. vs saline: 1104.3
Stroke, Volume 56, Issue Suppl_1 , Page AWP6-AWP6, February 1, 2025. Patients with increasing CT-CSVD scores were older (p<0.001), more likely to have hypertension (p<0.001), diabetes (p<0.001), coronary artery disease (p=0.044), and a higher baseline systolic bloodpressure (p=0.037).
Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
Nature Reviews Cardiology, Published online: 21 February 2025; doi:10.1038/s41569-025-01135-0 In this Review, Kirabo and colleagues discuss the mechanisms that underlie the sex-related differences in salt sensitivity of bloodpressure and hypertension, highlighting the implications for research and clinical practice.
Hypertension, Volume 82, Issue 1 , Page 136-148, January 1, 2025. Exposure to VOCs is associated with cardiovascular disease risk factors, including elevated bloodpressure in susceptible populations. had hypertension, and 7.9% had hypertension, and 7.9% had diabetes. had diabetes.
Stroke, Volume 56, Issue Suppl_1 , Page AWP7-AWP7, February 1, 2025. Introduction:Blood pressure is a simple physiologic parameter that is always measured, can be modulated, and may affect the outcome.
milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.
Stroke, Volume 56, Issue Suppl_1 , Page ATP282-ATP282, February 1, 2025. The main risk factor is hypertension, and bloodpressure (BP) control is crucial in the primary and secondary prevention of stroke. The 2020 AHA Guideline was used to define hypertension and target BP. Uncontrolled BP was observed in 60.9%
Stroke, Volume 56, Issue Suppl_1 , Page ATP266-ATP266, February 1, 2025. Effective bloodpressure (BP) management is crucial for reducing stroke and CVD risk, yet controlled hypertension remains suboptimal especially among minority populations. Background:Stroke is the 5thleading cause of death in the U.S. SD=15.8); 63.8%
Stroke, Volume 56, Issue Suppl_1 , Page ATP314-ATP314, February 1, 2025. Introduction:Blood pressure (BP) control after a stroke is crucial in lowering the risk of stroke recurrence. In comparison, among those with controlled BP (<130/80 mm Hg), the coverage was 63.0% for public, 33.6% for private, 1.9%
Stroke, Volume 56, Issue Suppl_1 , Page AWP287-AWP287, February 1, 2025. Introduction:Effective bloodpressure (BP) control post-stroke is a critical secondary prevention strategy. of participants had hypertension at baseline, and 31.6% years, with 52.6% There were 27.7% non-Hispanic whites, 28.8% Hispanics, and 39.3%
Stroke, Volume 56, Issue Suppl_1 , Page AWP47-AWP47, February 1, 2025. Enlarged perivascular spaces in the basal ganglia (EPVS-BG) are markers of hypertensive cerebral small vessel disease (HTN-cSVD) due to glymphatic system dysfunction.
Stroke, Volume 56, Issue Suppl_1 , Page AWP235-AWP235, February 1, 2025. Introduction:Insurance status may serve as an indicator of social and financial barriers that impede access to quality care. Disparities in outcomes of patients with ischemic stroke have been associated with insurance coverage.
Stroke, Volume 56, Issue Suppl_1 , Page AWP234-AWP234, February 1, 2025. Introduction:Education, a key modifiable social determinant of health, plays a significant role in shaping outcomes related to ischemic stroke.
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidney disease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. female, 22.1%
Stroke, Volume 56, Issue Suppl_1 , Page ATMP20-ATMP20, February 1, 2025. Data collection included demographics, risk factors, bloodpressures (BPs), and other variables such as the National Institute of Health Stroke Score (NIHSS), presence and types of large vessel occlusion, and severity of the hemorrhage (symptomatic or asymptomatic).Results:The
Stroke, Volume 56, Issue Suppl_1 , Page ATP274-ATP274, February 1, 2025. In multivariable analysis, only hypertension independently predicted stroke occurrence in the asymptomatic ICAS group (adjusted HR 4.06, 95%CI 1.60-10.33, Background:Intracranial artery stenosis (ICAS) is a progressive pathological process. 10.33, P = 0.003).Conclusions:The
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content